Procaine has been advocated in the treatment of malignant hyperpyrexia, whereas lignocaine has been shown to worsen the condition. Using muscle from patients susceptible to malignant hyperpyrexia in vitro, it has been demonstrated that muscle contracture can occur with procaine on its own, and in one patient the halothaneinduced contracture was potentiated by procaine. In other patients the concentration of procaine required to abolish the halothane-induced contracture was markedly above the clinical dose range. In a study of lignocaine and procaine on a caffeinated rat muscle (a suggested model for malignant hyperpyrexia) no significant difference was found in the ability of these local anaesthetics to alter resting tension of halothanetreated muscle; with both drugs the resting tension rose in a dose-related manner. The use of procaine as the drug of first choice in patients with malignant hyperpyrexia is challenged.
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In 1971 Beldavs et al. reported the successful use of procainamide in the treatment of a patient with malignant hyperpyrexia. The patient had developed malignant hyperpyrexia (42°C, 112°F) with muscle rigidity towards the end of an anaesthetic during which thiopentone, nitrous oxide, halothane and suxamethonium had been given. Procainamide 700 mg was administered over a period of 8 min and the temperature fell to 36.7°C (98°F) in 19 min with abolition of the muscle rigidity. The rationale for the use of procainamide was based on the observations of Feinstein (1963) who found that procaine hydrochloride blocked the rigor produced in frog muscle by caffeine. The effect of procainamide on myotonia had prompted Geschwind and Simpson (1955) to suggest its use clinically in the relief of muscle rigidity. Harrison has shown that when Landrace pigs were given halothane to provoke malignant hyperpyrexia there was a reduction in mortality after pretreatment with procaine (Harrison, 1971) . Using human hyperpyrexic muscle, Keaney and Ellis (1971) and Ellis (1973b) showed that pretreatment with procaine prevents and abolishes the contracture produced by halothan in vitro. We have confirmed these initial findings on eight muscle specimens taken from patients susceptible to malignant hyperpyrexia.
Since 1971 several patients have been given procaine or procainamide in the treatment of both the rigid and non-rigid varieties of malignant hyperpyrexia. Only three patients survived (Kalow et al., 1970; Maisel, Sessions and Miller, 1973; Barrett, 1973) and in one of these procaine seemed to have no effect on the rise in temperature. The nonsurvivors were given procaine or procainamide or lignocaine for their anti-arrhythmic actions rather than as a specific therapy for hyperpyrexia. Nevertheless, it has been suggested by several authors that a loading dose of up to 40 mg/kg procaine should be given even in the absence of muscle rigidity and this may be followed by an infusion of procaine 0.2 mg/kg/min. The negative inotropic effects of such large doses of procaine could be countered by isoprenaline.
For theoretical reasons procaine, which is known to accelerate calcium uptake into sarcoplasmic reticulum (Feinstein, 1963) and block the release of calcium from the sarcoplasmic reticulum by certain drugs (Thorpe and Seeman, 1973) should be more effective in malignant hyperpyrexia than lignocaine which enhances the leak of calcium from terminal sacs in the T-tubule system within the muscle. Yet lignocaine has been used in several patients with apparently beneficial results (Katz, 1970) .
We wish to report the results of in vitro investigations on both human muscle taken from patients susceptible to malignant hyperpyrexia, and animal muscle pretreated with caffeine. It has been shown (Harrison, 1973 ) that caffeinated rat muscle develops contracting with halothane in much the same way as muscle taken from patients susceptible to malignant hyperpyrexia treated with halothane (and most other inhalation anaesthetics) on its own Ellis, 1973a; Ellis et al., 1971 Ellis et al., , 1972 Ellis and Harriman, 1973) . Using a modification of the caffeine pretreated animal model, an experiment was devised to see if procaine and lignocaine differed in these actions on muscle.
METHODS
(i) The patients referred for investigation of susceptibility to malignant hyperpyrexia had a motor point muscle biopsy (Harriman, 1961) under modified general anaesthesia which avoided all the drugs known to induce malignant hyperpyrexia. The anaesthetic technique was developed especially for use in these patients and comprised intermittent thiopentone, fentanyl and nitrous oxide following diazepam premedication. Full temperature monitoring with cooling facilities was an obligatory part of the technique. Specimens of muscle were taken without stretching and placed in Krebs solution at room temperature for transport to the laboratory.
Strips of muscle 1 tim x 1 mm x 20 mm which included the motor nerve insertion were microdissected to remove non-viable tissue and attached by one end to the lower of two platinum stimulating electrodes in a tissue bath which was perfused with Krebs solution at 37 °C, pH 7.4, and gassed with 5% carbon dioxide in 95% oxygen. The upper free end of the muscle was attached by silk and silver chain to an isometric beam transducer. The muscle was directly stimulated supramaximally every 2 sec for 1 msec using a Medelec TS2 nerve stimulator. The isometric beam assembly was moved up and down by means of a constant speed motor and the length/tension curves so produced were displayed together with superimposed muscle twitches on a Devices M2 chart recorder.
Anaesthetic vapours were administered to the muscle by passing the gassing mixture through a variety of temperature-compensated vaporizers (Cyprane Ltd) and other drugs were dissolved in the perfusate. The muscle was stretched to a predetermined length (approximately 130% of resting length), held for 1 min to allow stress relaxation to subside and then allowed to return to the resting length. The tension developed after 1 min at maximum length was measured.
(ii) Sixteen adult male Wistar rats weighing 150-250 g were sacrificed. The left hemidiaphragm was immediately dissected out, with the attached phrenic nerve and costal margin, and immersed in fresh Krebs solution. Radial strips of muscle similar in size to those used for the human studies were microdissected and treated in the same way as the human specimens Caffeine 1 mM/litre was added to the perfusate and halothane 1% v/v was vaporized by the gassing mixture in order to produce the model of activated hyperpyrexia muscle.
Following control measurements, procaine or lignocaine 0.5-2 mM/litre was substituted for the perfusate and repeat isometric contractions measured. Because it has been shown (Grist, Hall and Baum, 1973 ) that some preservatives in local anaesthetic solutions have an adverse effect on muscle metabolism and may cause uncoupling of oxidative phorphorylation, the local anaesthetic solutions were made up from pure crystals dissolved in caffeinated Krebs solution.
Procaine crystals were added to the plain (uncaffeinated) Krebs solution used in the human study and its effect on muscle tension measured.
RESULTS
(i) There was an increase in tension in one human muscle specimen studied when procaine was added to the perfusate in the absence of halothane ( fig. 1 ). This patient is a member of a family known to be sensitive to malignant hyperpyrexia .
In muscle from two other patients from malignant hyperpyrexia susceptible families, halothane produced contracture in vitro which procaine pretreatment was unable to prevent. Moreover, procaine would not abolish established contracture except in gross overdosage equivalent to many times the whole body lethal dose.
(ii) In the rat caffeinated muscle preparation both procaine and lignocaine caused an increase in tension, the magnitude of which was related to the dose of local anaesthetic used ( fig. 2) . The dose/ response curves for the two drugs do not differ significantly (P>0.4).
DISCUSSION
It is important to study mammalian muscle at its normal temperature and pH since it is known that these are critical factors in determining the response of mammaiiati muscle to drugs. Bianchi and Bolton (1967) found that procaine caused muscle contracture at pH 8.2 but not at pH 7.4. Isaacson, Hinkes and Taylor (1970) found that the efFea of certain drugs, including procaine, on rat muscle was greatly modified by raising the temperature from 20 °C to 37°C and Britt and Kalow (1973, personal communication) have been unable to demonstrate contracture produced by halothane alone in human hyperpyrexia-sensitive muscle working at 25 "C, although this has been shown by Ellis at 37 °C and later confirmed by others (Moulds and Denborough, 1974; Bradley and Murchison, 1972) . Harrison, using a preparation of rat rectus abdominis muscle, has shown that caffeine and halothane together will produce contracture (Harri- son, 1973). This was produced by comparatively high concentrations of halothane (3% v/v) administered to a preparation maintained at a lower temperature than normal (30°C). The present study has confirmed the findings of earlier workers that evidence from mammalian muscle obtained in experiments at 20-30 °C may have no application to the same muscle at 37 °C. More important in the clinical context of malignant hyperpyrexia, the studies suggest that procaine should no longer be regarded as the drug of first choice in the treatment of a hyperpyrexic epsiode. Although in two published case reports procaine has apparently been effective in reversing the hyperpyrexic process, in our experience it has failed to have any beneficial effect. The dose may have to be so large that circulatory depression becomes a serious problem. From our experimental results, it appears that a third group of patients exists in whom procaine may exacerbate the contracture.
Therefore, rather than advocate procaine therapy for every patient who develops malignant hyperpyrexia, it should be reserved for those in whom other measures such as intravenous dexamethasone (Ellis et al., 1974) have failed to prevent a progressive increase in temperature or increasing rigor. Ideally in vitro testing of muscle should be performed to see if procaine has a beneficial effect, although the speed of development of hyperpyrexia mitigates against the usefulness of this procedure in the emergency situation.
UNE EVALUATION DE LA PROCAINE DANS LE TRAITEMENT DE L'HYPERPYREXIE MALIGNE
RESUME L'usage de la procaine a etc preconis£ dans le traitement de l'hyperpyrexie maligne tandis que Ton a montri que la lignocalne aggrave la condition du patient. En utilisant in vitro du muscle provenant de patients predisposes a l'hyperpyrexie maligne, on a demontr£ que la contracture musculaire peut se produire avec la procaine seule, et dans un patient, la contracture induite par rhalothanc a iti renforcee par la procaine. Dans d'autres patients, la concentration de procaine requise pour supprimer la contracture induite par lTialothane 6tait nettement superieure a la plage de doses cliniques. Dans une itude de la lignccaine et de la procaine sur un muscle de rat cafiiai (modele suggirf pour l'hyperpyrexie maligne), aucune difference appreciable n'a ete decouverte quant a l'aptitude de ces anesth£siants locaux a modifier la tension au repos du muscle traite a l'halothane. Avec les deux medicaments, la tension de repos a augmentd 'une maniere life a la dose. On met en doute la validity d'employer la procaine de preference a tout autre medicament pour les patients atteints d*hyperpyrexie maligne. Se ha abogado por la procaina en el tratamiento de la hiperpirexia maligna ya que la lignocaina ha demostrado empeorar el estado del paaenteTytilizando musculo del paciente susceptible de hiperpirexia maligna in vitro, se ha demostrado que la conlracci6n muscular puede realizarse con procaina, por si sola, y se aumento en un paciente la contracci6n, por induction con halotano, por medio de la procaina. En otros pacientes, la concentracion de procaina, requerida para suprimir la contracdon por inducci6n con halotano, estuvo muy por debajo de la dosis clinica. En un estudio de lignocaina y procaina sobre un musculo cafeinado de rata (modelo sugerido para hiperpirexia maHgna) no se encontnS ningiina difercncia sigmficativa en la habilidad de estos anestesicos locales para alterar la tensi6n de descanso del musculo tratado con halotano; con ambas drogas la tension de descanso result6 de acuerdo con la dosis. Se requiere el uso de procaina, corno droga de primera elecci6n, en pacientes con hiperpirexia maligna.,
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